Covalon Appoints New Board Director and Awards Deferred Share Units (DSUs)
Covalon Technologies Ltd., an advanced medical technologies company listed on the TSX Venture Exchange, has announced the appointment of Dr. Murray Miller to its Board of Directors as an independent director, subject to final approval from the TSX Venture Exchange.
The appointment marks the return of a familiar figure to the organization, as Dr. Miller previously served on Covalon’s Board from 2010 to 2019. His reappointment reflects the company’s continued focus on strengthening clinical expertise and governance as it advances its portfolio of wound care and infection prevention technologies.
Strengthening Clinical and Strategic Leadership
Dr. Miller brings more than four decades of medical experience to the Board. He graduated as a Medical Doctor from the University of Manitoba in 1982 and completed his residency in Radiology at the University of Toronto. Over the course of his career, he has worked as a practicing physician and clinical leader across hospitals and community healthcare settings in Ontario.
In addition to his clinical practice, Dr. Miller has held leadership positions within medical associations and has served in advisory roles for several biotechnology and medical technology companies. His background spans both frontline healthcare delivery and strategic advisory work in the life sciences sector, giving him a broad perspective on clinical needs, healthcare system challenges, and innovation adoption.
Covalon Technologies Ltd. noted that Dr. Miller’s prior experience on the Board, combined with his continued engagement as a substantial shareholder, positions him as a valuable contributor to the company’s long-term strategic direction.
Board Leadership Perspective on the Appointment
Commenting on the appointment, Abe Schwartz, Chair of the Covalon Board, expressed strong support for Dr. Miller’s return. He emphasized that Dr. Miller’s previous tenure on the Board provided him with deep familiarity with the company’s operations, culture, and strategic objectives.
According to Schwartz, Dr. Miller’s medical expertise and ongoing engagement with the healthcare system will help Covalon further advance its mission of developing and commercializing innovative medical technologies. His “creative energy,” as described by the Chair, is expected to contribute to the company’s continued growth and product development initiatives.
The Board highlighted that bringing back a former director with both clinical and governance experience allows Covalon to reinforce continuity while also leveraging institutional knowledge that is already aligned with the company’s long-term objectives.
Role and Responsibilities as Independent Director
As an independent director, Dr. Miller will be expected to contribute to oversight and governance functions, including strategic guidance, risk management, and evaluation of the company’s clinical and commercial development priorities.
Independent directors play a critical role in publicly traded life sciences companies by ensuring balanced decision-making, maintaining accountability, and supporting investor confidence. In Covalon’s case, the addition of a physician with extensive clinical experience is particularly relevant given the company’s focus on advanced wound care products and infection prevention solutions used in healthcare settings.
His appointment also reflects a broader trend in the medical technology sector, where companies increasingly seek board members with direct clinical experience to help guide product development and ensure alignment with real-world healthcare needs.
Compensation Structure and Equity Alignment
In connection with his appointment, Covalon Technologies Ltd. has granted Dr. Miller an aggregate of 22,222 Deferred Share Units (DSUs) in lieu of cash compensation for his annual director’s fees for fiscal year 2026.
The DSUs were issued under the company’s Amended and Restated Omnibus Long-Term Incentive Plan (LTIP), which was adopted effective March 25, 2026. Under the terms of the plan, the DSUs will vest 12 months from the date of grant, aligning director compensation with long-term shareholder value creation.
The deemed value of the DSUs was calculated based on the closing share price of Covalon’s common shares on the TSX Venture Exchange on June 8, 2026, which was $2.16 per share. This structure reflects a compensation approach commonly used in public companies to align board incentives with company performance over time.
In addition to Dr. Miller’s grant, the company also issued a total of 6,218 DSUs to certain directors as part of its obligation settlement under the LTIP. These equity-based awards are intended to support long-term alignment between board members and shareholders while conserving cash resources for operational and strategic initiatives.
Reinforcing Governance and Long-Term Incentive Alignment
The use of deferred share units as part of director compensation reflects Covalon’s broader governance strategy, which emphasizes long-term value creation and shareholder alignment. By tying compensation to share performance, the company aims to ensure that board members are incentivized to support sustainable growth and strategic decision-making.
Equity-based compensation mechanisms such as DSUs are commonly used in the medical technology and biotechnology sectors, where companies often prioritize capital efficiency and long-term development cycles. These instruments also help align the interests of directors with those of shareholders, particularly in early- to mid-stage growth companies operating in competitive healthcare markets.
Covalon’s Position in Advanced Medical Technologies
Covalon Technologies Ltd. is focused on developing advanced medical technologies, particularly in the areas of wound care, infection prevention, and medical device coatings. The company’s products are designed to improve patient outcomes while reducing healthcare-associated complications, such as infections and delayed wound healing.
The addition of Dr. Miller to the Board is expected to support Covalon’s ongoing efforts to expand its clinical validation, strengthen its product pipeline, and enhance its engagement with healthcare providers and institutional customers.
As healthcare systems continue to prioritize infection prevention and cost-effective treatment solutions, companies like Covalon are increasingly positioned to play a role in addressing both clinical and operational challenges in patient care.
Broader Industry Context and Leadership Trends
The appointment also reflects a broader trend across the medical technology industry, where boards are increasingly composed of individuals with diverse expertise spanning clinical practice, regulatory affairs, and healthcare innovation.
Physician representation at the board level is particularly valuable for companies developing products intended for direct clinical use, as it ensures that product development is informed by real-world medical experience and patient care considerations.
In this context, Dr. Miller’s background in radiology, hospital leadership, and medical advisory roles provides Covalon with a perspective that bridges clinical practice and strategic commercialization.
The appointment of Dr. Murray Miller to the Board of Covalon Technologies Ltd. represents a strategic reinforcement of the company’s governance and clinical expertise. With decades of medical experience and prior board service, Dr. Miller brings continuity, insight, and industry knowledge to Covalon at a time when the company continues to advance its portfolio of medical technologies.
Supported by an equity-aligned compensation structure and grounded in strong clinical leadership, the appointment reflects Covalon’s commitment to long-term value creation, innovation in healthcare technology, and closer alignment between medical expertise and corporate strategy.
About Covalon
Covalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF).
